SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Wallace DJ. The clinical presentation of systemic lupus erythematosus. In: WallaceDJ, HahnBH, editors. Duboi's lupus erythematosus. Baltimore (MD): Williams & Wilkins; 1997. p. 62733.
  • 2
    Reveille JD, Bartolucci A, Alarcón GS. Prognosis in systemic lupus erythematosus: negative impact of increasing age at onset, black race, and thrombocytopenia, as well as causes of death. Arthritis Rheum 1990; 33: 3748.
  • 3
    Quismorio FP Jr. Hematologic and lymphoid abnormalities in systemic lupus erythematosus. In: WallaceDJ, HahnBH, editors. Duboi's lupus erythematosus. Baltimore (MD): Williams & Wilkins; 1997. p. 793816.
  • 4
    Griner PF, Hoyer LW. Amegakaryocytic thrombocytopenia in systemic lupus erythematosus. Arch Intern Med 1970; 125: 32832.
  • 5
    Manoharan A, Williams NT, Sparrow R. Acquired amegakaryocytic thrombocytopenia: report of a case and review of literature. Q J Med 1989; 70: 23452.
  • 6
    Katai M, Aizawa T, Ohara N, Hiramatsu K, Hashizume K, Yamada T, et al. Acquired amegakaryocytic thrombocytopenic purpura with humoral inhibitory factor for megakaryocytic colony formation. Intern Med 1994; 33: 1479.
  • 7
    Nagasawa T, Sakurai T, Kashiwagi H, Abe T. Cell mediated amegakaryocytic thrombocytopenia associated with systemic lupus erythematosus. Blood 1986; 67: 47983.
  • 8
    Hoffman R. Acquired pure amegakaryocytic thrombocytopenia. Semin Hematol 1991; 28: 30312.
  • 9
    Kaushansky K. Thrombopoietin: the primary regulator of platelet production. Blood 1995; 86: 41931.
  • 10
    Wendling F, Maraskovsky E, Debili N, Florindo C, Teepe M, Titeux M, et al. cMpl ligand is a humoral regulator of megakaryocytopoiesis. Nature 1994; 369: 5714.
  • 11
    Ballmaier M, Germeshausen M, Schulze H, Cherkaoui K, Lang S, Gaudig A, et al. c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia. Blood 2001; 97: 13946.
  • 12
    Winchester RJ. Systemic lupus erythematosus: pathogenesis. In: KoopmanWJ, editor. Arthritis and Allied Conditions. Baltimore (MD): Williams & Wilkins; 1997. p. 136191.
  • 13
    Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 12717.
  • 14
    Karpatkin S. Autoimmune (idiopathic) thrombocytopenic purpura. Lancet 1997; 349: 15316.
  • 15
    Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992; 35: 63040.
  • 16
    Forman MS, Nakamura M, Mimori T, Gelpi C, Hardin JA. Detection of antibodies to small nuclear ribonucleoproteins and small cytoplasmic ribonucleoproteins using unlabelled cell extracts. Arthritis Rheum 1985; 28: 135661.
  • 17
    He R, Reid DM, Jones CE, Shulman NR. Spectrum of Ig classes, specificities, and titers of serum antiglycoproteins in chronic idiopathic thrombocytopenic purpura. Blood 1994; 83: 102432.
  • 18
    Kuwana M, Kaburaki J, Ikeda Y. Autoreactive T cells to platelet GPIIb-IIIa in immune thrombocytopenic purpura: role in production of anti-platelet autoantibody. J Clin Invest 1998; 102: 1393402.
  • 19
    Morita H, Tahara T, Matsumoto A, Kato T, Miyazaki H, Ohashi H. Functional analysis of the cytoplasmic domain of the human Mpl receptor for tyrosine-phosphorylation of the signaling molecules, proliferation and differentiation. FEBS Lett 1996; 395: 22834.
  • 20
    Hürlmann-Forster M, Steiner B, von Felten A. Quantitation of platelet-specific autoantibodies in platelet eluates of ITP patients measured by a novel ELISA using purified glycoprotein complexes GPIIb/IIIa and GPIb/IX as antigens. Br J Haematol 1997; 98: 32835.
  • 21
    Kuwana M, Medsger TA Jr, Wright TM. Detection of anti-DNA topoisomerase I antibody by an enzyme-linked immunosorbent assay using overlapping recombinant polypeptides. Clin Immunol Immunopathol 1995; 76: 26678.
  • 22
    Hagiwara T, Kodama I, Horie K, Kato T, Miyazaki H. Proliferative properties of human umbilical cord blood megakaryocyte progenitor cells to human thrombopoietin. Exp Hematol 1998; 26: 22835.
  • 23
    Shiozaki H, Miyawaki S, Kuwaki T, Hagiwara T, Kato T, Miyazaki H. Autoantibodies neutralizing thrombopoietin in a patient with amegakaryocytic thrombocytopenic purpura. Blood 2000; 95: 21878.
  • 24
    Schrezenmeier H, Griesshammer M, Hornkohl A, Nichol JL, Hecht T, Heimpel H, et al. Thrombopoietin serum levels in patients with aplastic anaemia: correlation with platelet count and persistent elevation in remission. Br J Haematol 1998; 100: 5716.
  • 25
    Hill W, Landgraf R. Successful treatment of amegakaryocytic thrombocytopenic purpura with cyclosporin. N Engl J Med 1985; 312: 10601.
  • 26
    Hoffman R, Zaknoen S, Yang HH, Bruno E, LoBuglio AF, Arrowsmith JB, et al. An antibody cytotoxic to megakaryocyte progenitor cells in a patient with immune thrombocytopenic purpura. N Engl J Med 1985; 312: 11704.
  • 27
    Gewirtz AM, Sacchetti MK, Bien R, Barry WE. Cell-mediated suppression of megakaryocytopoiesis in acquired amegakaryocytic thrombocytopenic purpura. Blood 1986; 68: 61926.
  • 28
    Benedetti F, de Sabata D, Perona G. T suppressor activated lymphocytes (CD8+/DR+) inhibit megakaryocyte progenitor cell differentiation in a case of acquired amegakaryocytic thrombocytopenic purpura. Stem Cells 1994; 12: 20513.
  • 29
    Mukai HY, Kojima H, Tadokoro K, Tahara T, Kato T, Hasegawa Y, et al. Serum thrombopoietin (TPO) levels in patients with amegakaryocytic thrombocytopenia are much higher than those with immune thrombocytopenic purpura. Thromb Haemost 1996; 76: 6758.
  • 30
    Fielder PJ, Hass P, Nagel M, Stefanich E, Widmer R, Bennett GL, et al. Human platelets as a model for the binding and degradation of thrombopoietin. Blood 1997; 89: 27828.
  • 31
    Ichikawa N, Ishida F, Shimodaira S, Tahara T, Kato T, Kitano K. Regulation of serum thrombopoietin levels by platelets and megakaryocytes in patients with aplastic anaemia and idiopathic thrombocytopenic purpura. Thromb Haemost 1996; 76: 15660.
  • 32
    McMillan R. Chronic idiopathic thrombocytopenic purpura. N Engl J Med 1981; 304: 113547.
  • 33
    Schmidt KG, Rasmussen JW. Kinetics and distribution in vivo of 111In-labelled autologous platelet turnover in idiopathic thrombocytopenic purpura. Scand J Haematol 1985; 34: 4756.
  • 34
    Ballem PJ, Segal GM, Stratton JR, Gernsheimer T, Adamson JW, Slichter SJ. Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura: evidence of both impaired platelet production and increased platelet clearance. J Clin Invest 1987; 80: 3340.
  • 35
    McMillan R, Luiken GA, Levy R, Yelenosky R, Longmire RL. Antibody against megakaryocytes in idiopathic thrombocytopenic purpura. JAMA 1978; 239: 24602.
  • 36
    Berchtold P, Wenger M. Autoantibodies against platelet glycoproteins in autoimmune thrombocytopenic purpura: their clinical significance and response to treatment. Blood 1993; 81: 124650.
  • 37
    Macchi L, Rispal P, Clofent-Sanchez G, Pellegrin JL, Nurden P, Leng B, et al. Anti-platelet antibodies in patients with systemic lupus erythematosus and the primary antiphospholipid antibody syndrome: their relationship with the observed thrombocytopenia. Br J Haematol 1997; 98: 33641.
  • 38
    Broudy VC, Lin NL, Sabath DF, Papayannopoulou T, Kaushansky K. Human platelets display high-affinity receptors for thrombopoietin. Blood 1997; 89: 1896904.